Early-phase administration of human amnion-derived stem cells ameliorates neurobehavioral deficits of intracerebral hemorrhage by suppressing local inflammation and apoptosis

Background Intracerebral hemorrhage (ICH) is a significant cause of death and disabilities. Recently, cell therapies using mesenchymal stem cells have been shown to improve ICH-induced neurobehavioral deficits. Based on these findings, we designed this study to evaluate the therapeutic efficacy and...

Full description

Saved in:
Bibliographic Details
Published inJournal of neuroinflammation Vol. 19; no. 1; pp. 48 - 19
Main Authors Kuramoto, Yoji, Fujita, Mitsugu, Takagi, Toshinori, Takeda, Yuki, Doe, Nobutaka, Yamahara, Kenichi, Yoshimura, Shinichi
Format Journal Article
LanguageEnglish
Published London BioMed Central 12.02.2022
BioMed Central Ltd
BMC
Subjects
Abdominal surgery
Amnion
Amnion - metabolism
Amnion - pathology
Amniotic sac
Animals
Apoptosis
Biomedical and Life Sciences
Biomedicine
Bone marrow
CD11b antigen
CD45 antigen
Cell death
Cell number
Cerebral Hemorrhage - metabolism
Cesarean Section
Clinical trials
Complications and side effects
Cytokines
Experiments
Female
Flow cytometry
Graft versus host disease
Health aspects
Hemorrhage
Human amnion-derived stem cell
Humans
Immunology
Inflammation
Inflammation - metabolism
Inflammation - therapy
Intracerebral hemorrhage
Intravenous administration
Lesions
Macrophage
Macrophages
Mesenchymal Stem Cell Transplantation - methods
Mesenchymal Stem Cells - metabolism
Mesenchyme
Mice
Microglia
Neurobiology
Neurology
Neurosciences
Nitric-oxide synthase
Pregnancy
Prevention
Splenocytes
Stem cell transplantation
Stem cells
Tumor necrosis factor-α
Western blotting
Japan
Inflammation
Human amnion-derived stem cell
Intracerebral hemorrhage
Macrophage
Microglia
Apoptosis
Online AccessGet full text
ISSN1742-2094
1742-2094
DOI10.1186/s12974-022-02411-3

Cover

Abstract Background Intracerebral hemorrhage (ICH) is a significant cause of death and disabilities. Recently, cell therapies using mesenchymal stem cells have been shown to improve ICH-induced neurobehavioral deficits. Based on these findings, we designed this study to evaluate the therapeutic efficacy and underlying mechanisms by which human amnion-derived stem cells (hAMSCs) would ameliorate neurobehavioral deficits of ICH-bearing hosts. Methods hAMSCs were induced from amnia obtained by cesarean section and administered intravenously to ICH-bearing mice during the acute phase. The mice were then subject to multitask neurobehavioral tests at the subacute phase. We attempted to optimize the dosage and timing of the hAMSC administrations. In parallel with the hAMSCs, a tenfold higher dose of human adipose-derived stem cells (ADSCs) were used as an experimental control. Specimens were obtained from the ICH lesions to conduct immunostaining, flow cytometry, and Western blotting to elucidate the underlying mechanisms of the hAMSC treatment. Results The intravenous administration of hAMSCs to the ICH-bearing mice effectively improved their neurobehavioral deficits, particularly when the treatment was initiated at Day 1 after the ICH induction. Of note, the hAMSCs promoted clinical efficacy equivalent to or better than that of hADSCs at 1/10 the cell number. The systemically administered hAMSCs were found in the ICH lesions along with the local accumulation of macrophages/microglia. In detail, the hAMSC treatment decreased the number of CD11b + CD45 + and Ly6G + cells in the ICH lesions, while splenocytes were not affected. Moreover, the hAMSC treatment decreased the number of apoptotic cells in the ICH lesions. These results were associated with suppression of the protein expression levels of macrophage-related factors iNOS and TNFα. Conclusions Intravenous hAMSC administration during the acute phase would improve ICH-induced neurobehavioral disorders. The underlying mechanism was suggested to be the suppression of subacute inflammation and apoptosis by suppressing macrophage/microglia cell numbers and macrophage functions (such as TNFα and iNOS). From a clinical point of view, hAMSC-based treatment may be a novel strategy for the treatment of ICH.
AbstractList Abstract Background Intracerebral hemorrhage (ICH) is a significant cause of death and disabilities. Recently, cell therapies using mesenchymal stem cells have been shown to improve ICH-induced neurobehavioral deficits. Based on these findings, we designed this study to evaluate the therapeutic efficacy and underlying mechanisms by which human amnion-derived stem cells (hAMSCs) would ameliorate neurobehavioral deficits of ICH-bearing hosts. Methods hAMSCs were induced from amnia obtained by cesarean section and administered intravenously to ICH-bearing mice during the acute phase. The mice were then subject to multitask neurobehavioral tests at the subacute phase. We attempted to optimize the dosage and timing of the hAMSC administrations. In parallel with the hAMSCs, a tenfold higher dose of human adipose-derived stem cells (ADSCs) were used as an experimental control. Specimens were obtained from the ICH lesions to conduct immunostaining, flow cytometry, and Western blotting to elucidate the underlying mechanisms of the hAMSC treatment. Results The intravenous administration of hAMSCs to the ICH-bearing mice effectively improved their neurobehavioral deficits, particularly when the treatment was initiated at Day 1 after the ICH induction. Of note, the hAMSCs promoted clinical efficacy equivalent to or better than that of hADSCs at 1/10 the cell number. The systemically administered hAMSCs were found in the ICH lesions along with the local accumulation of macrophages/microglia. In detail, the hAMSC treatment decreased the number of CD11b+CD45+ and Ly6G+ cells in the ICH lesions, while splenocytes were not affected. Moreover, the hAMSC treatment decreased the number of apoptotic cells in the ICH lesions. These results were associated with suppression of the protein expression levels of macrophage-related factors iNOS and TNFα. Conclusions Intravenous hAMSC administration during the acute phase would improve ICH-induced neurobehavioral disorders. The underlying mechanism was suggested to be the suppression of subacute inflammation and apoptosis by suppressing macrophage/microglia cell numbers and macrophage functions (such as TNFα and iNOS). From a clinical point of view, hAMSC-based treatment may be a novel strategy for the treatment of ICH.
Background Intracerebral hemorrhage (ICH) is a significant cause of death and disabilities. Recently, cell therapies using mesenchymal stem cells have been shown to improve ICH-induced neurobehavioral deficits. Based on these findings, we designed this study to evaluate the therapeutic efficacy and underlying mechanisms by which human amnion-derived stem cells (hAMSCs) would ameliorate neurobehavioral deficits of ICH-bearing hosts. Methods hAMSCs were induced from amnia obtained by cesarean section and administered intravenously to ICH-bearing mice during the acute phase. The mice were then subject to multitask neurobehavioral tests at the subacute phase. We attempted to optimize the dosage and timing of the hAMSC administrations. In parallel with the hAMSCs, a tenfold higher dose of human adipose-derived stem cells (ADSCs) were used as an experimental control. Specimens were obtained from the ICH lesions to conduct immunostaining, flow cytometry, and Western blotting to elucidate the underlying mechanisms of the hAMSC treatment. Results The intravenous administration of hAMSCs to the ICH-bearing mice effectively improved their neurobehavioral deficits, particularly when the treatment was initiated at Day 1 after the ICH induction. Of note, the hAMSCs promoted clinical efficacy equivalent to or better than that of hADSCs at 1/10 the cell number. The systemically administered hAMSCs were found in the ICH lesions along with the local accumulation of macrophages/microglia. In detail, the hAMSC treatment decreased the number of CD11b+CD45+ and Ly6G+ cells in the ICH lesions, while splenocytes were not affected. Moreover, the hAMSC treatment decreased the number of apoptotic cells in the ICH lesions. These results were associated with suppression of the protein expression levels of macrophage-related factors iNOS and TNFα. Conclusions Intravenous hAMSC administration during the acute phase would improve ICH-induced neurobehavioral disorders. The underlying mechanism was suggested to be the suppression of subacute inflammation and apoptosis by suppressing macrophage/microglia cell numbers and macrophage functions (such as TNFα and iNOS). From a clinical point of view, hAMSC-based treatment may be a novel strategy for the treatment of ICH.
Background Intracerebral hemorrhage (ICH) is a significant cause of death and disabilities. Recently, cell therapies using mesenchymal stem cells have been shown to improve ICH-induced neurobehavioral deficits. Based on these findings, we designed this study to evaluate the therapeutic efficacy and underlying mechanisms by which human amnion-derived stem cells (hAMSCs) would ameliorate neurobehavioral deficits of ICH-bearing hosts. Methods hAMSCs were induced from amnia obtained by cesarean section and administered intravenously to ICH-bearing mice during the acute phase. The mice were then subject to multitask neurobehavioral tests at the subacute phase. We attempted to optimize the dosage and timing of the hAMSC administrations. In parallel with the hAMSCs, a tenfold higher dose of human adipose-derived stem cells (ADSCs) were used as an experimental control. Specimens were obtained from the ICH lesions to conduct immunostaining, flow cytometry, and Western blotting to elucidate the underlying mechanisms of the hAMSC treatment. Results The intravenous administration of hAMSCs to the ICH-bearing mice effectively improved their neurobehavioral deficits, particularly when the treatment was initiated at Day 1 after the ICH induction. Of note, the hAMSCs promoted clinical efficacy equivalent to or better than that of hADSCs at 1/10 the cell number. The systemically administered hAMSCs were found in the ICH lesions along with the local accumulation of macrophages/microglia. In detail, the hAMSC treatment decreased the number of CD11b + CD45 + and Ly6G + cells in the ICH lesions, while splenocytes were not affected. Moreover, the hAMSC treatment decreased the number of apoptotic cells in the ICH lesions. These results were associated with suppression of the protein expression levels of macrophage-related factors iNOS and TNFα. Conclusions Intravenous hAMSC administration during the acute phase would improve ICH-induced neurobehavioral disorders. The underlying mechanism was suggested to be the suppression of subacute inflammation and apoptosis by suppressing macrophage/microglia cell numbers and macrophage functions (such as TNFα and iNOS). From a clinical point of view, hAMSC-based treatment may be a novel strategy for the treatment of ICH.
Intracerebral hemorrhage (ICH) is a significant cause of death and disabilities. Recently, cell therapies using mesenchymal stem cells have been shown to improve ICH-induced neurobehavioral deficits. Based on these findings, we designed this study to evaluate the therapeutic efficacy and underlying mechanisms by which human amnion-derived stem cells (hAMSCs) would ameliorate neurobehavioral deficits of ICH-bearing hosts. hAMSCs were induced from amnia obtained by cesarean section and administered intravenously to ICH-bearing mice during the acute phase. The mice were then subject to multitask neurobehavioral tests at the subacute phase. We attempted to optimize the dosage and timing of the hAMSC administrations. In parallel with the hAMSCs, a tenfold higher dose of human adipose-derived stem cells (ADSCs) were used as an experimental control. Specimens were obtained from the ICH lesions to conduct immunostaining, flow cytometry, and Western blotting to elucidate the underlying mechanisms of the hAMSC treatment. The intravenous administration of hAMSCs to the ICH-bearing mice effectively improved their neurobehavioral deficits, particularly when the treatment was initiated at Day 1 after the ICH induction. Of note, the hAMSCs promoted clinical efficacy equivalent to or better than that of hADSCs at 1/10 the cell number. The systemically administered hAMSCs were found in the ICH lesions along with the local accumulation of macrophages/microglia. In detail, the hAMSC treatment decreased the number of CD11b.sup.+CD45.sup.+ and Ly6G.sup.+ cells in the ICH lesions, while splenocytes were not affected. Moreover, the hAMSC treatment decreased the number of apoptotic cells in the ICH lesions. These results were associated with suppression of the protein expression levels of macrophage-related factors iNOS and TNF[alpha]. Intravenous hAMSC administration during the acute phase would improve ICH-induced neurobehavioral disorders. The underlying mechanism was suggested to be the suppression of subacute inflammation and apoptosis by suppressing macrophage/microglia cell numbers and macrophage functions (such as TNF[alpha] and iNOS). From a clinical point of view, hAMSC-based treatment may be a novel strategy for the treatment of ICH.
Intracerebral hemorrhage (ICH) is a significant cause of death and disabilities. Recently, cell therapies using mesenchymal stem cells have been shown to improve ICH-induced neurobehavioral deficits. Based on these findings, we designed this study to evaluate the therapeutic efficacy and underlying mechanisms by which human amnion-derived stem cells (hAMSCs) would ameliorate neurobehavioral deficits of ICH-bearing hosts. hAMSCs were induced from amnia obtained by cesarean section and administered intravenously to ICH-bearing mice during the acute phase. The mice were then subject to multitask neurobehavioral tests at the subacute phase. We attempted to optimize the dosage and timing of the hAMSC administrations. In parallel with the hAMSCs, a tenfold higher dose of human adipose-derived stem cells (ADSCs) were used as an experimental control. Specimens were obtained from the ICH lesions to conduct immunostaining, flow cytometry, and Western blotting to elucidate the underlying mechanisms of the hAMSC treatment. The intravenous administration of hAMSCs to the ICH-bearing mice effectively improved their neurobehavioral deficits, particularly when the treatment was initiated at Day 1 after the ICH induction. Of note, the hAMSCs promoted clinical efficacy equivalent to or better than that of hADSCs at 1/10 the cell number. The systemically administered hAMSCs were found in the ICH lesions along with the local accumulation of macrophages/microglia. In detail, the hAMSC treatment decreased the number of CD11b CD45 and Ly6G cells in the ICH lesions, while splenocytes were not affected. Moreover, the hAMSC treatment decreased the number of apoptotic cells in the ICH lesions. These results were associated with suppression of the protein expression levels of macrophage-related factors iNOS and TNFα. Intravenous hAMSC administration during the acute phase would improve ICH-induced neurobehavioral disorders. The underlying mechanism was suggested to be the suppression of subacute inflammation and apoptosis by suppressing macrophage/microglia cell numbers and macrophage functions (such as TNFα and iNOS). From a clinical point of view, hAMSC-based treatment may be a novel strategy for the treatment of ICH.
Background Intracerebral hemorrhage (ICH) is a significant cause of death and disabilities. Recently, cell therapies using mesenchymal stem cells have been shown to improve ICH-induced neurobehavioral deficits. Based on these findings, we designed this study to evaluate the therapeutic efficacy and underlying mechanisms by which human amnion-derived stem cells (hAMSCs) would ameliorate neurobehavioral deficits of ICH-bearing hosts. Methods hAMSCs were induced from amnia obtained by cesarean section and administered intravenously to ICH-bearing mice during the acute phase. The mice were then subject to multitask neurobehavioral tests at the subacute phase. We attempted to optimize the dosage and timing of the hAMSC administrations. In parallel with the hAMSCs, a tenfold higher dose of human adipose-derived stem cells (ADSCs) were used as an experimental control. Specimens were obtained from the ICH lesions to conduct immunostaining, flow cytometry, and Western blotting to elucidate the underlying mechanisms of the hAMSC treatment. Results The intravenous administration of hAMSCs to the ICH-bearing mice effectively improved their neurobehavioral deficits, particularly when the treatment was initiated at Day 1 after the ICH induction. Of note, the hAMSCs promoted clinical efficacy equivalent to or better than that of hADSCs at 1/10 the cell number. The systemically administered hAMSCs were found in the ICH lesions along with the local accumulation of macrophages/microglia. In detail, the hAMSC treatment decreased the number of CD11b.sup.+CD45.sup.+ and Ly6G.sup.+ cells in the ICH lesions, while splenocytes were not affected. Moreover, the hAMSC treatment decreased the number of apoptotic cells in the ICH lesions. These results were associated with suppression of the protein expression levels of macrophage-related factors iNOS and TNF[alpha]. Conclusions Intravenous hAMSC administration during the acute phase would improve ICH-induced neurobehavioral disorders. The underlying mechanism was suggested to be the suppression of subacute inflammation and apoptosis by suppressing macrophage/microglia cell numbers and macrophage functions (such as TNF[alpha] and iNOS). From a clinical point of view, hAMSC-based treatment may be a novel strategy for the treatment of ICH. Keywords: Human amnion-derived stem cell, Intracerebral hemorrhage, Macrophage, Microglia, Apoptosis, Inflammation
Intracerebral hemorrhage (ICH) is a significant cause of death and disabilities. Recently, cell therapies using mesenchymal stem cells have been shown to improve ICH-induced neurobehavioral deficits. Based on these findings, we designed this study to evaluate the therapeutic efficacy and underlying mechanisms by which human amnion-derived stem cells (hAMSCs) would ameliorate neurobehavioral deficits of ICH-bearing hosts.BACKGROUNDIntracerebral hemorrhage (ICH) is a significant cause of death and disabilities. Recently, cell therapies using mesenchymal stem cells have been shown to improve ICH-induced neurobehavioral deficits. Based on these findings, we designed this study to evaluate the therapeutic efficacy and underlying mechanisms by which human amnion-derived stem cells (hAMSCs) would ameliorate neurobehavioral deficits of ICH-bearing hosts.hAMSCs were induced from amnia obtained by cesarean section and administered intravenously to ICH-bearing mice during the acute phase. The mice were then subject to multitask neurobehavioral tests at the subacute phase. We attempted to optimize the dosage and timing of the hAMSC administrations. In parallel with the hAMSCs, a tenfold higher dose of human adipose-derived stem cells (ADSCs) were used as an experimental control. Specimens were obtained from the ICH lesions to conduct immunostaining, flow cytometry, and Western blotting to elucidate the underlying mechanisms of the hAMSC treatment.METHODShAMSCs were induced from amnia obtained by cesarean section and administered intravenously to ICH-bearing mice during the acute phase. The mice were then subject to multitask neurobehavioral tests at the subacute phase. We attempted to optimize the dosage and timing of the hAMSC administrations. In parallel with the hAMSCs, a tenfold higher dose of human adipose-derived stem cells (ADSCs) were used as an experimental control. Specimens were obtained from the ICH lesions to conduct immunostaining, flow cytometry, and Western blotting to elucidate the underlying mechanisms of the hAMSC treatment.The intravenous administration of hAMSCs to the ICH-bearing mice effectively improved their neurobehavioral deficits, particularly when the treatment was initiated at Day 1 after the ICH induction. Of note, the hAMSCs promoted clinical efficacy equivalent to or better than that of hADSCs at 1/10 the cell number. The systemically administered hAMSCs were found in the ICH lesions along with the local accumulation of macrophages/microglia. In detail, the hAMSC treatment decreased the number of CD11b+CD45+ and Ly6G+ cells in the ICH lesions, while splenocytes were not affected. Moreover, the hAMSC treatment decreased the number of apoptotic cells in the ICH lesions. These results were associated with suppression of the protein expression levels of macrophage-related factors iNOS and TNFα.RESULTSThe intravenous administration of hAMSCs to the ICH-bearing mice effectively improved their neurobehavioral deficits, particularly when the treatment was initiated at Day 1 after the ICH induction. Of note, the hAMSCs promoted clinical efficacy equivalent to or better than that of hADSCs at 1/10 the cell number. The systemically administered hAMSCs were found in the ICH lesions along with the local accumulation of macrophages/microglia. In detail, the hAMSC treatment decreased the number of CD11b+CD45+ and Ly6G+ cells in the ICH lesions, while splenocytes were not affected. Moreover, the hAMSC treatment decreased the number of apoptotic cells in the ICH lesions. These results were associated with suppression of the protein expression levels of macrophage-related factors iNOS and TNFα.Intravenous hAMSC administration during the acute phase would improve ICH-induced neurobehavioral disorders. The underlying mechanism was suggested to be the suppression of subacute inflammation and apoptosis by suppressing macrophage/microglia cell numbers and macrophage functions (such as TNFα and iNOS). From a clinical point of view, hAMSC-based treatment may be a novel strategy for the treatment of ICH.CONCLUSIONSIntravenous hAMSC administration during the acute phase would improve ICH-induced neurobehavioral disorders. The underlying mechanism was suggested to be the suppression of subacute inflammation and apoptosis by suppressing macrophage/microglia cell numbers and macrophage functions (such as TNFα and iNOS). From a clinical point of view, hAMSC-based treatment may be a novel strategy for the treatment of ICH.
ArticleNumber 48
Audience Academic
Author Kuramoto, Yoji
Takagi, Toshinori
Yamahara, Kenichi
Fujita, Mitsugu
Doe, Nobutaka
Takeda, Yuki
Yoshimura, Shinichi
Author_xml – sequence: 1
  givenname: Yoji
  surname: Kuramoto
  fullname: Kuramoto, Yoji
  organization: Department of Neurosurgery, Hyogo College of Medicine
– sequence: 2
  givenname: Mitsugu
  surname: Fujita
  fullname: Fujita, Mitsugu
  email: mfujita47@med.kindai.ac.jp
  organization: Department of Neurosurgery, Hyogo College of Medicine, Center for Medical Education and Clinical Training, Kindai University Faculty of Medicine
– sequence: 3
  givenname: Toshinori
  surname: Takagi
  fullname: Takagi, Toshinori
  organization: Department of Neurosurgery, Hyogo College of Medicine
– sequence: 4
  givenname: Yuki
  surname: Takeda
  fullname: Takeda, Yuki
  organization: Department of Neurosurgery, Hyogo College of Medicine
– sequence: 5
  givenname: Nobutaka
  surname: Doe
  fullname: Doe, Nobutaka
  organization: Laboratory of Neurogenesis and CNS Repair, Hyogo College of Medicine, Laboratory of Psychology, General Education Center, Hyogo University of Health Science
– sequence: 6
  givenname: Kenichi
  surname: Yamahara
  fullname: Yamahara, Kenichi
  organization: Laboratory of Medical Innovation, Institute for Advanced Medical Sciences, Hyogo College of Medicine
– sequence: 7
  givenname: Shinichi
  orcidid: 0000-0001-5633-9132
  surname: Yoshimura
  fullname: Yoshimura, Shinichi
  email: hyogoneuro@yahoo.co.jp
  organization: Department of Neurosurgery, Hyogo College of Medicine, Laboratory of Medical Innovation, Institute for Advanced Medical Sciences, Hyogo College of Medicine
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35151317$$D View this record in MEDLINE/PubMed
BookMark eNp9ks1q3DAUhU1JaX7aF-iiGLrpxql-LEuzKYSQtoFAN-1ayPKVrcGWXMkemJfqM1YeJ00mlGCM7XvP_fA9OufZifMOsuw9RpcYi-pzxGTDywIRku4S44K-ys4wL0lB0KY8efJ-mp3HuEWIElaRN9kpZZhhivlZ9udGhX5fjJ2KkKtmsM7GKajJepd7k3fzoFyuBpe-iwaC3UGTxwmGXEPfx9SB3vqkh5g7mIOvoVO7pdLnDRir7RQXjnUJqiFAvXQ6GHwInWohr_d5nMcxQIzWtXnvdepbZ3o1DOtfKNfkavTj5KONb7PXRvUR3t0_L7JfX29-Xn8v7n58u72-uit0hfhUCMZ1QxpKCCBNk0sVKGqw1sAqbIzmIBjC1NQMgGitjaAlVmDqWolmgxi9yG5XbuPVVo7BDirspVdWHgo-tFKFyeoeJMIACpeKa8bKKpGpgKrUiBvKa8oW1peVNc71AI2GxYv-CHrccbaTrd9JIUrEeZkAn-4Bwf-eIU5ysHHxXznwc5SkIqLinIkqST8-k279HFyyKqkoYlggIR5VrUoLJLf9cjoLVF5VG1qJDUU0qS7_o0pXA4PVKYrGpvrRwIeni_7b8CFtSSBWgQ4-xgBGpnwcTjmRbS8xkkuw5RpsmYItD8GWC5s8G32gvzhE16GYxK6F8OjGC1N_AcCuD0s
CitedBy_id crossref_primary_10_1007_s10571_023_01325_9
crossref_primary_10_4103_NRR_NRR_D_23_01889
crossref_primary_10_1007_s12975_023_01216_7
crossref_primary_10_1093_stcltm_szad031
crossref_primary_10_3389_fcell_2024_1464727
crossref_primary_10_3389_fnmol_2024_1516119
crossref_primary_10_3389_fncel_2023_1080344
crossref_primary_10_1038_s41419_024_06620_x
Cites_doi 10.1016/j.brainres.2018.12.042
10.1002/JLB.3RU1018-378RR
10.1097/00004647-200002000-00022
10.1172/JCI59643
10.1007/s12975-010-0017-5
10.3109/14653249.2010.549122
10.3171/jns.2006.104.2.313
10.1002/sctm.18-0079
10.1186/2050-7771-2-1
10.1055/s-0036-1581995
10.1016/S0022-510X(01)00557-3
10.1038/s41536-019-0073-8
10.1371/journal.pone.0070180
10.1038/s41419-020-2279-5
10.1111/j.1471-4159.2006.04414.x
10.1002/jor.24412
10.1136/bmjgast-2018-000206
10.1155/2012/658356
10.1016/j.brainres.2019.01.037
10.3791/4289
10.1007/s10456-013-9381-6
10.3389/fimmu.2021.617163
10.1016/j.bcp.2007.07.005
10.3727/096368913X665594
10.1097/CCM.0000000000001425
10.1089/scd.2014.0146
10.1371/journal.pone.0087400
10.12659/MSM.900512
10.1186/s12974-019-1602-5
10.1016/S1474-4422(17)30046-7
10.1186/s12974-015-0284-x
10.1146/annurev.cellbio.17.1.387
10.1159/000233255
10.1038/nrc1910
10.1016/j.yjmcc.2012.06.020
10.1111/j.1471-4159.2009.06300.x
10.1161/STROKEAHA.111.626648
10.1186/1742-2094-11-98
10.3389/fncel.2021.653367
10.1046/j.1365-2141.2003.04329.x
10.1002/stem.1503
10.1016/S0140-6736(13)60986-1
10.3389/fimmu.2017.00626
10.1161/STROKEAHA.110.596718
10.1016/j.transproceed.2006.12.019
10.1177/0271678X15621499
10.1371/journal.pone.0088319
10.1016/j.imlet.2018.10.007
10.1172/JCI29950
10.1161/STROKEAHA.119.026392
10.1161/01.STR.0000149615.51204.0b
10.1038/nrrheum.2015.169
10.1056/NEJMoa1214609
10.1186/s13041-016-0225-3
10.1371/journal.pone.0103818
10.1155/2015/816460
10.1016/S1474-4422(09)70340-0
10.1165/rcmb.2015-0295OC
10.1136/bmjopen-2018-026403
ContentType Journal Article
Copyright The Author(s) 2022
2022. The Author(s).
COPYRIGHT 2022 BioMed Central Ltd.
2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2022
– notice: 2022. The Author(s).
– notice: COPYRIGHT 2022 BioMed Central Ltd.
– notice: 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7T5
7TK
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s12974-022-02411-3
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Immunology Abstracts
Neurosciences Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One
ProQuest Central
Proquest Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Neurosciences Abstracts
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Immunology Abstracts
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
Publicly Available Content Database


MEDLINE

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 5
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1742-2094
EndPage 19
ExternalDocumentID oai_doaj_org_article_01eea14a7c55467e838e64c07f37b355
PMC8840774
A693689303
35151317
10_1186_s12974_022_02411_3
Genre Journal Article
GeographicLocations Japan
GeographicLocations_xml – name: Japan
GrantInformation_xml – fundername: JSPS KAKENHI Grant-in-Aid for Scientific Research (C)
  grantid: 19K09539
– fundername: MEXT-Supported Program for the Strategic Research Foundation at Private Universities
  grantid: S1511034
– fundername: ;
  grantid: S1511034
– fundername: ;
  grantid: 19K09539
GroupedDBID ---
0R~
29L
2WC
53G
5GY
5VS
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAWTL
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CS3
DIK
DU5
E3Z
EBD
EBLON
EBS
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IHR
INH
INR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PJZUB
PPXIY
PQQKQ
PROAC
PSQYO
PUEGO
RBZ
RNS
ROL
RPM
RSV
SBL
SOJ
TR2
TUS
UKHRP
WOQ
WOW
XSB
~8M
AAYXX
ALIPV
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
PMFND
3V.
7T5
7TK
7XB
8FK
AZQEC
DWQXO
H94
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c607t-857cd2d322e0c32976ea3f1cce561ffc7e85013fb5ee2cccf8341aefbba8d9053
IEDL.DBID M48
ISSN 1742-2094
IngestDate Wed Aug 27 01:22:39 EDT 2025
Thu Aug 21 14:10:21 EDT 2025
Thu Sep 04 22:29:07 EDT 2025
Fri Jul 25 01:59:32 EDT 2025
Tue Jun 17 21:05:47 EDT 2025
Tue Jun 10 20:36:38 EDT 2025
Thu Apr 03 07:09:31 EDT 2025
Tue Jul 01 02:54:35 EDT 2025
Thu Apr 24 22:51:55 EDT 2025
Sat Sep 06 07:29:56 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Inflammation
Human amnion-derived stem cell
Intracerebral hemorrhage
Macrophage
Microglia
Apoptosis
Language English
License 2022. The Author(s).
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c607t-857cd2d322e0c32976ea3f1cce561ffc7e85013fb5ee2cccf8341aefbba8d9053
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0001-5633-9132
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12974-022-02411-3
PMID 35151317
PQID 2630518088
PQPubID 55345
PageCount 19
ParticipantIDs doaj_primary_oai_doaj_org_article_01eea14a7c55467e838e64c07f37b355
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8840774
proquest_miscellaneous_2628677586
proquest_journals_2630518088
gale_infotracmisc_A693689303
gale_infotracacademiconefile_A693689303
pubmed_primary_35151317
crossref_citationtrail_10_1186_s12974_022_02411_3
crossref_primary_10_1186_s12974_022_02411_3
springer_journals_10_1186_s12974_022_02411_3
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-02-12
PublicationDateYYYYMMDD 2022-02-12
PublicationDate_xml – month: 02
  year: 2022
  text: 2022-02-12
  day: 12
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Journal of neuroinflammation
PublicationTitleAbbrev J Neuroinflammation
PublicationTitleAlternate J Neuroinflammation
PublicationYear 2022
Publisher BioMed Central
BioMed Central Ltd
BMC
Publisher_xml – name: BioMed Central
– name: BioMed Central Ltd
– name: BMC
References X Gao (2411_CR33) 2010; 1
PR Krafft (2411_CR23) 2012
GC Sharp (2411_CR32) 2013; 8
K Matsushita (2411_CR29) 2000; 20
J Chen (2411_CR41) 2001; 189
PO Girodet (2411_CR51) 2016; 55
YH Gong (2411_CR56) 2021; 15
BJ Bain (2411_CR12) 2003; 121
T Roszer (2411_CR53) 2015; 2015
Bernstein JE, Savla P, Dong F, Zampella B, Wiginton JG, Miulli DE, Wacker MR, Menoni R (2411_CR62) 2018; 10
TJ Kean (2411_CR44) 2013; 2013
Y Ikegame (2411_CR13) 2011; 13
S Otagiri (2411_CR22) 2018; 5
A Sica (2411_CR45) 2012; 122
J Xie (2411_CR10) 2016; 22
K Tatebayashi (2411_CR24) 2019; 1712
CM Raynaud (2411_CR15) 2012; 2012
H Min (2411_CR1) 2016; 9
K Yamahara (2411_CR19) 2019; 9
CJ van Asch (2411_CR3) 2010; 9
N Jetten (2411_CR54) 2014; 17
T Takagi (2411_CR26) 2017; 37
X Zhao (2411_CR28) 2007; 101
AD Mendelow (2411_CR5) 2013; 382
W Fan (2411_CR35) 2014; 32
K Mishiro (2411_CR25) 2014; 9
M Feldmann (2411_CR60) 1994; 43
K Yamahara (2411_CR14) 2014; 9
J Aronowski (2411_CR40) 2011; 42
M Chen (2411_CR59) 2015; 12
D Seyfried (2411_CR37) 2006; 104
HK Lee (2411_CR8) 2014; 23
H Tsuda (2411_CR17) 2014; 23
FK Swirski (2411_CR48) 2007; 117
J Yang (2411_CR46) 2014; 2
Y Li (2411_CR38) 2020; 11
JD Cherry (2411_CR49) 2014; 11
S Miyamoto (2411_CR20) 2017; 9
D Fukumura (2411_CR58) 2006; 6
Y Kuramoto (2411_CR11) 2019; 1711
JE Jung (2411_CR34) 2011; 42
R Borem (2411_CR16) 2019; 37
W Liao (2411_CR42) 2009; 24
IL Weissman (2411_CR7) 2001; 17
X Cao (2411_CR31) 2009; 111
R Lim (2411_CR21) 2018; 7
DC Hess (2411_CR9) 2017; 16
N Nowroozilarki (2411_CR50) 2018; 204
Y Kaku (2411_CR52) 2014; 9
S Schrepfer (2411_CR43) 2007; 39
K Shkirkova (2411_CR2) 2020; 51
LX Wang (2411_CR55) 2019; 106
S Dabrowska (2411_CR36) 2019; 16
N Graubardt (2411_CR47) 2017; 8
Y Takada (2411_CR61) 2007; 74
Y Silva (2411_CR63) 2005; 36
S Mei (2411_CR64) 2021; 12
GD Kalliolias (2411_CR57) 2016; 12
MT Turnbull (2411_CR39) 2019; 4
M Ohshima (2411_CR18) 2012; 53
P Yang (2411_CR27) 2016; 44
AI Qureshi (2411_CR30) 2003; 52
CS Anderson (2411_CR4) 2013; 368
MF Saulle (2411_CR6) 2016; 36
References_xml – volume: 1711
  start-page: 58
  year: 2019
  ident: 2411_CR11
  publication-title: Brain Res
  doi: 10.1016/j.brainres.2018.12.042
– volume: 106
  start-page: 345
  year: 2019
  ident: 2411_CR55
  publication-title: J Leukoc Biol
  doi: 10.1002/JLB.3RU1018-378RR
– volume: 20
  start-page: 396
  year: 2000
  ident: 2411_CR29
  publication-title: J Cereb Blood Flow Metab
  doi: 10.1097/00004647-200002000-00022
– volume: 122
  start-page: 787
  year: 2012
  ident: 2411_CR45
  publication-title: J Clin Invest
  doi: 10.1172/JCI59643
– volume: 1
  start-page: 202
  year: 2010
  ident: 2411_CR33
  publication-title: Transl Stroke Res
  doi: 10.1007/s12975-010-0017-5
– volume: 13
  start-page: 675
  year: 2011
  ident: 2411_CR13
  publication-title: Cytotherapy
  doi: 10.3109/14653249.2010.549122
– volume: 104
  start-page: 313
  year: 2006
  ident: 2411_CR37
  publication-title: J Neurosurg
  doi: 10.3171/jns.2006.104.2.313
– volume: 7
  start-page: 628
  year: 2018
  ident: 2411_CR21
  publication-title: Stem Cells Transl Med
  doi: 10.1002/sctm.18-0079
– volume: 43
  start-page: 179
  year: 1994
  ident: 2411_CR60
  publication-title: Circ Shock
– volume: 2
  start-page: 1
  year: 2014
  ident: 2411_CR46
  publication-title: Biomark Res
  doi: 10.1186/2050-7771-2-1
– volume: 36
  start-page: 306
  year: 2016
  ident: 2411_CR6
  publication-title: Semin Neurol
  doi: 10.1055/s-0036-1581995
– volume: 189
  start-page: 49
  year: 2001
  ident: 2411_CR41
  publication-title: J Neurol Sci
  doi: 10.1016/S0022-510X(01)00557-3
– volume: 4
  start-page: 10
  year: 2019
  ident: 2411_CR39
  publication-title: npj Regen Med
  doi: 10.1038/s41536-019-0073-8
– volume: 8
  start-page: e70180
  year: 2013
  ident: 2411_CR32
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0070180
– volume: 11
  start-page: 72
  year: 2020
  ident: 2411_CR38
  publication-title: Cell Death Dis
  doi: 10.1038/s41419-020-2279-5
– volume: 101
  start-page: 652
  year: 2007
  ident: 2411_CR28
  publication-title: J Neurochem
  doi: 10.1111/j.1471-4159.2006.04414.x
– volume: 37
  start-page: 2445
  year: 2019
  ident: 2411_CR16
  publication-title: J Orthop Res
  doi: 10.1002/jor.24412
– volume: 5
  start-page: e000206
  year: 2018
  ident: 2411_CR22
  publication-title: BMJ Open Gastroenterol
  doi: 10.1136/bmjgast-2018-000206
– volume: 2012
  start-page: 658356
  year: 2012
  ident: 2411_CR15
  publication-title: Stem Cells Int
  doi: 10.1155/2012/658356
– volume: 1712
  start-page: 139
  year: 2019
  ident: 2411_CR24
  publication-title: Brain Res
  doi: 10.1016/j.brainres.2019.01.037
– year: 2012
  ident: 2411_CR23
  publication-title: J Vis Exp
  doi: 10.3791/4289
– volume: 17
  start-page: 109
  year: 2014
  ident: 2411_CR54
  publication-title: Angiogenesis
  doi: 10.1007/s10456-013-9381-6
– volume: 10
  start-page: e3529
  year: 2018
  ident: 2411_CR62
  publication-title: Cureus
– volume: 12
  start-page: 617163
  year: 2021
  ident: 2411_CR64
  publication-title: Front Immunol.
  doi: 10.3389/fimmu.2021.617163
– volume: 52
  start-page: 1041
  year: 2003
  ident: 2411_CR30
  publication-title: Neurosurgery
– volume: 74
  start-page: 1057
  year: 2007
  ident: 2411_CR61
  publication-title: Biochem Pharmacol
  doi: 10.1016/j.bcp.2007.07.005
– volume: 23
  start-page: 889
  year: 2014
  ident: 2411_CR17
  publication-title: Cell Transplant
  doi: 10.3727/096368913X665594
– volume: 44
  start-page: e390
  year: 2016
  ident: 2411_CR27
  publication-title: Crit Care Med
  doi: 10.1097/CCM.0000000000001425
– volume: 2013
  start-page: 732742
  year: 2013
  ident: 2411_CR44
  publication-title: Stem Cells Int
– volume: 23
  start-page: 2851
  year: 2014
  ident: 2411_CR8
  publication-title: Stem Cells Dev
  doi: 10.1089/scd.2014.0146
– volume: 9
  start-page: e87400
  year: 2014
  ident: 2411_CR52
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0087400
– volume: 22
  start-page: 3552
  year: 2016
  ident: 2411_CR10
  publication-title: Med Sci Monit
  doi: 10.12659/MSM.900512
– volume: 16
  start-page: 216
  year: 2019
  ident: 2411_CR36
  publication-title: J Neuroinflamm
  doi: 10.1186/s12974-019-1602-5
– volume: 16
  start-page: 360
  year: 2017
  ident: 2411_CR9
  publication-title: Lancet Neurol
  doi: 10.1016/S1474-4422(17)30046-7
– volume: 12
  start-page: 61
  year: 2015
  ident: 2411_CR59
  publication-title: J Neuroinflamm
  doi: 10.1186/s12974-015-0284-x
– volume: 17
  start-page: 387
  year: 2001
  ident: 2411_CR7
  publication-title: Annu Rev Cell Dev Biol
  doi: 10.1146/annurev.cellbio.17.1.387
– volume: 24
  start-page: 307
  year: 2009
  ident: 2411_CR42
  publication-title: Cell Physiol Biochem
  doi: 10.1159/000233255
– volume: 6
  start-page: 521
  issue: 7
  year: 2006
  ident: 2411_CR58
  publication-title: Nat Rev Cancer.
  doi: 10.1038/nrc1910
– volume: 53
  start-page: 420
  year: 2012
  ident: 2411_CR18
  publication-title: J Mol Cell Cardiol
  doi: 10.1016/j.yjmcc.2012.06.020
– volume: 111
  start-page: 101
  year: 2009
  ident: 2411_CR31
  publication-title: J Neurochem
  doi: 10.1111/j.1471-4159.2009.06300.x
– volume: 42
  start-page: 3574
  year: 2011
  ident: 2411_CR34
  publication-title: Stroke
  doi: 10.1161/STROKEAHA.111.626648
– volume: 11
  start-page: 98
  year: 2014
  ident: 2411_CR49
  publication-title: J Neuroinflamm
  doi: 10.1186/1742-2094-11-98
– volume: 15
  start-page: 653367
  year: 2021
  ident: 2411_CR56
  publication-title: Front Cell Neurosci
  doi: 10.3389/fncel.2021.653367
– volume: 121
  start-page: 949
  year: 2003
  ident: 2411_CR12
  publication-title: Br J Haematol
  doi: 10.1046/j.1365-2141.2003.04329.x
– volume: 32
  start-page: 473
  year: 2014
  ident: 2411_CR35
  publication-title: Stem Cells
  doi: 10.1002/stem.1503
– volume: 382
  start-page: 397
  year: 2013
  ident: 2411_CR5
  publication-title: Lancet
  doi: 10.1016/S0140-6736(13)60986-1
– volume: 8
  start-page: 626
  year: 2017
  ident: 2411_CR47
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2017.00626
– volume: 42
  start-page: 1781
  year: 2011
  ident: 2411_CR40
  publication-title: Stroke
  doi: 10.1161/STROKEAHA.110.596718
– volume: 39
  start-page: 573
  year: 2007
  ident: 2411_CR43
  publication-title: Transplant Proc
  doi: 10.1016/j.transproceed.2006.12.019
– volume: 37
  start-page: 123
  year: 2017
  ident: 2411_CR26
  publication-title: J Cereb Blood Flow Metab
  doi: 10.1177/0271678X15621499
– volume: 9
  start-page: e88319
  year: 2014
  ident: 2411_CR14
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0088319
– volume: 204
  start-page: 67
  year: 2018
  ident: 2411_CR50
  publication-title: Immunol Lett
  doi: 10.1016/j.imlet.2018.10.007
– volume: 117
  start-page: 195
  year: 2007
  ident: 2411_CR48
  publication-title: J Clin Invest
  doi: 10.1172/JCI29950
– volume: 51
  start-page: 784
  year: 2020
  ident: 2411_CR2
  publication-title: Stroke
  doi: 10.1161/STROKEAHA.119.026392
– volume: 36
  start-page: 86
  year: 2005
  ident: 2411_CR63
  publication-title: Stroke
  doi: 10.1161/01.STR.0000149615.51204.0b
– volume: 12
  start-page: 49
  issue: 1
  year: 2016
  ident: 2411_CR57
  publication-title: Nat Rev Rheumatol.
  doi: 10.1038/nrrheum.2015.169
– volume: 368
  start-page: 2355
  year: 2013
  ident: 2411_CR4
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1214609
– volume: 9
  start-page: 940
  year: 2017
  ident: 2411_CR20
  publication-title: Am J Transl Res
– volume: 9
  start-page: 42
  year: 2016
  ident: 2411_CR1
  publication-title: Mol Brain
  doi: 10.1186/s13041-016-0225-3
– volume: 9
  start-page: e103818
  year: 2014
  ident: 2411_CR25
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0103818
– volume: 2015
  start-page: 816460
  year: 2015
  ident: 2411_CR53
  publication-title: Mediat Inflamm
  doi: 10.1155/2015/816460
– volume: 9
  start-page: 167
  year: 2010
  ident: 2411_CR3
  publication-title: Lancet Neurol
  doi: 10.1016/S1474-4422(09)70340-0
– volume: 55
  start-page: 467
  year: 2016
  ident: 2411_CR51
  publication-title: Am J Respir Cell Mol Biol
  doi: 10.1165/rcmb.2015-0295OC
– volume: 9
  start-page: e026403
  year: 2019
  ident: 2411_CR19
  publication-title: BMJ Open
  doi: 10.1136/bmjopen-2018-026403
SSID ssj0032562
Score 2.3810956
Snippet Background Intracerebral hemorrhage (ICH) is a significant cause of death and disabilities. Recently, cell therapies using mesenchymal stem cells have been...
Intracerebral hemorrhage (ICH) is a significant cause of death and disabilities. Recently, cell therapies using mesenchymal stem cells have been shown to...
Background Intracerebral hemorrhage (ICH) is a significant cause of death and disabilities. Recently, cell therapies using mesenchymal stem cells have been...
Abstract Background Intracerebral hemorrhage (ICH) is a significant cause of death and disabilities. Recently, cell therapies using mesenchymal stem cells have...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 48
SubjectTerms Abdominal surgery
Amnion
Amnion - metabolism
Amnion - pathology
Amniotic sac
Animals
Apoptosis
Biomedical and Life Sciences
Biomedicine
Bone marrow
CD11b antigen
CD45 antigen
Cell death
Cell number
Cerebral Hemorrhage - metabolism
Cesarean Section
Clinical trials
Complications and side effects
Cytokines
Experiments
Female
Flow cytometry
Graft versus host disease
Health aspects
Hemorrhage
Human amnion-derived stem cell
Humans
Immunology
Inflammation
Inflammation - metabolism
Inflammation - therapy
Intracerebral hemorrhage
Intravenous administration
Lesions
Macrophage
Macrophages
Mesenchymal Stem Cell Transplantation - methods
Mesenchymal Stem Cells - metabolism
Mesenchyme
Mice
Microglia
Neurobiology
Neurology
Neurosciences
Nitric-oxide synthase
Pregnancy
Prevention
Splenocytes
Stem cell transplantation
Stem cells
Tumor necrosis factor-α
Western blotting
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gLojwDBRkJiQNYzdN2jgVRVUjlRKXeLMcPdqUliTZZJP5UfyMzdrJtioALx43HWdsznm8cjz8T8sY6q03DYX6L1LFSeM10WVasllXlHF6dFrj0zr_ws4vy82V1eeOqL8wJi_TAceCO08w5nZVaGMynEk4W0vHSpMIXogGwRO-b1um8mIo-uAAgz-cjMpIfD4BqomSYuQ6YhMR9CxgKbP2_--QboHQ7YfLWrmkAo9MH5P4URdKT2PpDcse1D8nd82mf_BG5CrzFrF8BRlG94MelnafhYj6qv7fwm1mwwR_OUmR0pvgdf4ASt8Gj-xCG0kB4eX2Yn1qHnBPjgO9ZYzuN2-Lm84auMGl3uwIHRZufdNj1Mce2_UYDYIK0B_OLRyWpbi3VfdeP3bAeHpOL009fP56x6WYGZngqRiYrYWxuwRm41BQwttzpwmfGOAjHvDegpgpiS9-AvnNjjJcAltr5ptHS1jDvn5CDtmvdM0IhYEotRBl147Oy8oXWvvLW1I0Mm81FQrJZUcpMtOV4e8ZGheWL5CoqV4FyVVCugjrv9nX6SNrxV-kPqP-9JBJuhwdghmoyQ_UvM0zIW7QehW4Bh15Ppxugk0iwpU54XXCIDVP4u6OFJExnsyye7U9N7mRQOQe3nElAhIS83hdjTUyRa123Q5kcuQkryRPyNJrrvksFRK0ZRIoJEQtDXvR5WdKuV4FsXEpY8osyIe9nk79u1p_H9Pn_GNMX5F4epyzL8iNyMG537iWEgGPzKsz2X31sWqA
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bb9MwFLZgSIgXxJ2MgYyExANYy9V2ntBATBPSeGJS3yzHl7VSl4QmRdqf4jdyjpOmZIg9tnba2Of22T7-DiHvrLPaVBzsW8SO5cJrpvO8YKUsCuewdFrg0jv_zs8u8m-LYjFuuHVjWuXOJwZHbRuDe-THKQfNTCQYxaf2J8OqUXi6OpbQuEvuJYBEsHSDWEwLrgzCebq7KCP5cQexTeQM89chMiF93ywYBc7-fz3zX6HpZtrkjbPTEJJOH5GHI5akJ4PwH5M7rn5C7p-Pp-VPye_AXszaJUQqqmcsubTxNJTno_qqhs_Mgib-cpYirzPF3fwOWtwaL_ADGKWB9nJ_pZ9ah8wTfYe_s8L3NG6DR9BrusTU3c0S3BStrmm3bYdM2_qShrAJvT0o4XBhkuraUt02bd90q-4ZuTj9-uPLGRvrMzDDY9EzWQhjUwsuwcUmg7nlTmc-McYBKPPeCCcLQJi-AqmnxhgvIWRq56tKS1uC9T8nB3VTu5eEAmyKLWCNsvJJXvhMa194a8pKhiPnLCLJTlDKjOTlWENjrcIiRnI1CFeBcFUQroJnPkzPtAN1x629P6P8p55Iux2-aDaXarRiFSfO6STXwmByH4wvk47nJhY-ExUgt4i8R-1R6Bxw6vV4xwEGiTRb6oSXGQeEGMPfHc16glGbefNO_9ToVDq1N4GIvJ2a8UlMlKtds8U-KTIUFpJH5MWgrtOQMsCuCeDFiIiZIs_GPG-pV8tAOS4lLPxFHpGPO5Xfv9b_5_Tw9lG8Ig_SwRhZkh6Rg36zda8B4vXVm2DHfwCau1K2
  priority: 102
  providerName: ProQuest
– databaseName: Springer Nature OA Free Journals
  dbid: C6C
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Zb9QwELagSIgXxE2gICMh8QAWuXzksayoKqTyRKW-WY4PdqUliTZZpP6p_kZmnOy2KYfE467Hu7HndGbmMyFvnXfG1gL0W6aelTIYZsqSs0px7j1enRax9E6_ipOz8ss5P59gcrAX5nr-PlPiYw_-SJYMa87BmyDk3m1yh4PhRWleiMXO6hbguvNdU8wf580cT8Tn_90KX3NDN0skb-RJo_s5fkDuT3EjPRoZ_ZDc8s0jcvd0yow_JpcRqZh1S_BK1MwQcWkbaLyKj5ofDXxmDqTup3cUMZwpvrnvYcSvsVkfAk8aIS6v2vep84gyMfT4Oyt8Tus3mG5e0yWW6W6WYJJofUH7bTdW1TbfaXSRQB1A4MbmSGoaR03XdkPbr_on5Oz487fFCZvuYmBWpHJgikvrcgfq71NbwN4Kb4qQWeshAAvBSq84RJOhBg7n1tqgwD0aH-raKFeBpj8lB03b-OeEQoiUOogrqjpkJQ-FMYEHZ6taxfRykZBsxyhtJ6ByvC9jreOBRQk9MlcDc3VkroY57_dzuhGm45_Un5D_e0qE2I5fgOTpSWN1mnlvstJIi4V8sL5CeVHaVIZC1hClJeQdSo9GQ4Bbb6Z-BlgkQmrpI1EVAqLBFP7ucEYJCmznwzv505MB6XUuwBBnCnxAQt7sh3EmFsU1vt0iTY5ohFyJhDwbxXW_pALi1Axiw4TImSDP1jwfaVbLCC-u4MwPh4KEfNiJ_NVj_X1PX_wf-UtyLx-Vk2X5ITkYNlv_CsK7oX4d9foXI5tLhw
  priority: 102
  providerName: Springer Nature
Title Early-phase administration of human amnion-derived stem cells ameliorates neurobehavioral deficits of intracerebral hemorrhage by suppressing local inflammation and apoptosis
URI https://link.springer.com/article/10.1186/s12974-022-02411-3
https://www.ncbi.nlm.nih.gov/pubmed/35151317
https://www.proquest.com/docview/2630518088
https://www.proquest.com/docview/2628677586
https://pubmed.ncbi.nlm.nih.gov/PMC8840774
https://doaj.org/article/01eea14a7c55467e838e64c07f37b355
Volume 19
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1bb9MwFLZ2kRAviDsZozISEg8QyNV2HhDqqk1TpU0IqNQ3y3HstVJJStNO7E_xGznHSToyBuKpamwnsX1uzjnnO4S8KkyhdM6Av3lg_IRb5askSf1MpKkxWDrNYemdnbPTSTKeptMd0pU7ahewvvVoh_WkJqvFux_frz4Cw39wDC_Y-xp0Fk98jEsHjYOwfLtk3_mLMJQv2XoVYlDvUZMgGQF1ZEmXRHPrPXqKyuH5_ym1f1NbN0Mqb_hVnbo6uU_utXYmHTaE8YDsmPIhuXPWetIfkZ8O2dhfzkCLUdVD0KWVpa50H1XfSvjvF0Cll6agiPlM8Ut_DS1mgcn9YKhSB4l5ne5PC4OoFOsa7zPH99Rmhe7pBZ1hWO9qBiKM5le03iybKNzygjqVCr0tEGiTTElVWVC1rJbrqp7Xj8nk5Pjr6NRvazf4mgV87YuU6yIqQFyYQMewtsyo2IZaGzDYrNXciBSsT5sDRURaaytAnSpj81yJIgPJ8ITslVVpnhEKJlVQgB2S5TZMUhsrZVNb6CwXzh0deyTsNkrqFtgc62sspDvgCCabzZWwudJtroQxb7Zjlg2sxz97H-H-b3siJLe7UK0uZMvhMgiNUWGiuMbAP5hfLAxLdMBtzHOw6jzyGqlHIinj0qs2_wEmiRBccsiymIH1GMDjDns9geF1v7mjP9nxi4wYCO5QgM7wyMttM47EILrSVBvsEyF6YSqYR5425LqdUgx2bQi2pEd4j5B7c-63lPOZgyMXIgngEOGRtx3JX7_W39f04L-X4zm5GzV86YfRIdlbrzbmBViC63xAdvmUD8j-cDj-Mobfo-PzT5_h6oiNBu7rysAJgF8UUmG9
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLamTgJeEHcCA4wE4gGi5R7nYUIbbOrYWiG0SXszji9rpZKEpgXtT_ET-G2c4yQtGWJve2xtt3bO7XN8_B1CXimthMwTsO_U026UGuGKKIrdjMWx1lg6zXLpjcbJ8DT6dBafbZDf3V0YTKvsfKJ11KqU-I58O0hAM30GRvG--u5i1Sg8Xe1KaIi2tILasRRj7cWOI33xE7Zw9c7hR5D36yA42D_5MHTbKgOuTLx04bI4lSpQoNjak2EA4VmL0PhSaoAWxshUsxhwkslh7oGU0jBw_EKbPBdMZR5WjYAQsBnhC5QB2dzbH3_-0sWCEABF0F3VYcl2DdE1jVzMoIfYiASCvXBoqwb8Gxv-Co6XEzcvnd7aoHhwh9xu0SzdbdTvLtnQxT1yY9Se198nvyx_sltNIFZS0ePppaWhtkAgFd8K-OwqsIUfWlFklqZ4nlBDi54hhQDAYWqJN9ekAlRp5L5Y1Pg7U5yn1HM8BJ_RCSYPzyfgKGl-Qetl1eT6FufUBm7obcAMmiubVBSKiqqsFmU9rR-Q02uR3UMyKMpCPyYUgJunAO1kufGj2IRCmNgomeXMHnqHDvE7QXHZ0qdjFY8Zt9solvBGuByEy61wOYx5uxpTNeQhV_beQ_mveiLxt_2inJ_z1o9wz9da-JFIJaYXwvpCppNIeqkJ0xywo0PeoPZwdE_46EV7ywIWiURffDfJwgQwqgd_t9XrCW5F9ps7_eOtW6v52ggd8nLVjCMxVa_Q5RL7BMiRGLPEIY8adV0tKQT07ANidUjaU-TemvstxXRiSc8ZizzYqjjkXafy62n9_5k-uXoVL8jN4cnomB8fjo-ekltBY5iuH2yRwWK-1M8AcC7y561VU_L1uh3JH5UKmDI
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Zb9QwELaglSpeEDeBAkZC4gGi5rSdx-WoykIrJKjUN8vx0V1pSaJNFok_xW9kxkm2TTkkHnc93o09pzMznwl5YaxRumSg3zyyYcadClWW5WEh8txavDrNY-kdn7Cj02x-lp9d6uL31e5jSrLvaUCUpqo7aIzrVVywgxa8FM9CrEQHH4NAfNfJrsiLAo5fu7PZ_Mt8tMYpuPRkbJb548yJQ_K4_b9b50vu6Wrp5JX8qXdLh7fIzSGepLNeAG6Ta7a6Q_aOh4z5XfLTIxiHzQK8FVUTpFxaO-qv6KPqWwWfQwPS-N0aitjOFN_otzBiV9jEDwEp9dCXF2391FhEn-ha_J0lPqe2a0xDr-gCy3fXCzBVtPxB203TV9tW59S7TqB2IIh90yRVlaGqqZuubpftPXJ6-P7r26NwuKMh1CziXShyrk1iwCzYSKewt8yq1MVaWwjMnNPcihyiTFcC5xOttRPgNpV1ZamEKcAC3Cc7VV3Zh4RC6BQZiDeK0sVZ7lKlXO6MLkrh085pQOKRUVIPAOZ4j8ZK-oOMYLJnrgTmSs9cCXNebec0PXzHP6nfIP-3lAi97b-o1-dy0GQZxdaqOFNcY4EfrC8VlmU64i7lJURvAXmJ0iPRQODWq6HPARaJUFtyxoqUQZQYwd_tTyhBsfV0eJQ_ORiWViYMDHQswDcE5Pl2GGdisVxl6w3SJIhSmAsWkAe9uG6XlEL8GkPMGBA-EeTJmqcj1XLhYceFgMM_zwLyehT5i8f6-54--j_yZ2Tv87tD-enDycfH5EbS62kYJ_tkp1tv7BOIALvy6aDkvwB9i1g0
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Early-phase+administration+of+human+amnion-derived+stem+cells+ameliorates+neurobehavioral+deficits+of+intracerebral+hemorrhage+by+suppressing+local+inflammation+and+apoptosis&rft.jtitle=Journal+of+neuroinflammation&rft.au=Kuramoto%2C+Yoji&rft.au=Fujita%2C+Mitsugu&rft.au=Takagi%2C+Toshinori&rft.au=Takeda%2C+Yuki&rft.date=2022-02-12&rft.pub=BioMed+Central+Ltd&rft.issn=1742-2094&rft.eissn=1742-2094&rft.volume=19&rft.issue=1&rft_id=info:doi/10.1186%2Fs12974-022-02411-3&rft.externalDocID=A693689303
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1742-2094&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1742-2094&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1742-2094&client=summon